Listed

XBiotech Inc.: Form 10-K/A for the period ended Dec 31, 2018

Filed with the SEC on Mar 15, 2019 and accepted by EDGAR at Mar 15, 2019, 13:09 ET.

Share

Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2018-01-01 to 2018-12-31$15.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-10-01 to 2018-12-31−$6.1mus-gaap:OperatingIncomeLoss
Operating income12 months2018-01-01 to 2018-12-31−$21.0mus-gaap:OperatingIncomeLoss
Income tax12 months2018-01-01 to 2018-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-10-01 to 2018-12-31−$6.1mus-gaap:NetIncomeLoss
Net income12 months2018-01-01 to 2018-12-31−$21.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-10-01 to 2018-12-31−$0.17us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2018-01-01 to 2018-12-31−$16.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$122.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-12-31$15.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$17.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$44.3mus-gaap:Assets
Current liabilitiesAt period end2018-12-31$2.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-12-31$2.9mus-gaap:Liabilities
Shareholders' equityAt period end2018-12-31$41.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-19-001758. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.